ZAI LAB LIMITED Investment Income, Interest
ZAI LAB LIMITED (ZLAB) reported Investment Income, Interest of $5.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-06
- ZAI LAB LIMITED investment income, interest for the quarter ending 2026-06-30 was $5.88M, a 33.52% decline year-over-year.
- ZAI LAB LIMITED investment income, interest for the quarter ending 2026-03-31 was $6.45M, a 25.09% decline year-over-year.
- ZAI LAB LIMITED investment income, interest for the quarter ending 2025-12-31 was $7.25M, a 20.18% decline year-over-year.
- ZAI LAB LIMITED investment income, interest for the quarter ending 2025-09-30 was $8.35M, a 7.58% decline year-over-year.
- ZAI LAB LIMITED investment income, interest for fiscal 2025 was $33.05M, a 10.93% decline from fiscal 2024.
- ZAI LAB LIMITED investment income, interest for fiscal 2024 was $37.10M, a 6.76% decline from fiscal 2023.
- ZAI LAB LIMITED investment income, interest for fiscal 2023 was $39.80M, a 172.92% increase from fiscal 2022.
- ZAI LAB LIMITED investment income, interest for fiscal 2022 was $14.58M, a 565.84% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month | Investment Income, Interest 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $5.88M 10-Q · filed 2026-08-06 | $12.33M 10-Q · filed 2026-08-06 | $19.58M derived: sum of 3 quarters · filed 2026-08-06 | $27.93M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $6.45M 10-Q · filed 2026-05-07 | $13.70M derived: sum of 2 quarters · filed 2026-05-07 | $22.05M derived: sum of 3 quarters · filed 2026-05-07 | $30.89M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $7.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $15.60M derived: sum of 2 quarters · filed 2026-02-26 | $24.44M derived: sum of 3 quarters · filed 2026-08-06 | $33.05M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $8.35M 10-Q · filed 2025-11-06 | $17.19M derived: sum of 2 quarters · filed 2026-08-06 | $25.79M 10-Q · filed 2025-11-06 | $34.88M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $8.84M 10-Q · filed 2026-08-06 | $17.45M 10-Q · filed 2026-08-06 | $26.54M derived: sum of 3 quarters · filed 2026-08-06 | $35.57M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $8.61M 10-Q · filed 2026-05-07 | $17.69M derived: sum of 2 quarters · filed 2026-05-07 | $26.72M derived: sum of 3 quarters · filed 2026-05-07 | $36.05M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $9.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $18.12M derived: sum of 2 quarters · filed 2026-02-26 | $27.45M derived: sum of 3 quarters · filed 2026-02-26 | $37.10M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $9.03M 10-Q · filed 2025-11-06 | $18.36M derived: sum of 2 quarters · filed 2025-11-06 | $28.02M 10-Q · filed 2025-11-06 | $38.32M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $9.33M 10-Q · filed 2025-08-07 | $18.99M 10-Q · filed 2025-08-07 | $29.29M derived: sum of 3 quarters · filed 2026-02-26 | $38.46M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $9.66M 10-Q · filed 2025-05-08 | $19.96M derived: sum of 2 quarters · filed 2026-02-26 | $29.13M derived: sum of 3 quarters · filed 2026-02-26 | $39.22M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $10.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $19.48M derived: sum of 2 quarters · filed 2026-02-26 | $29.57M derived: sum of 3 quarters · filed 2026-02-26 | $39.80M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $9.17M 10-Q · filed 2024-11-12 | $19.26M derived: sum of 2 quarters · filed 2024-11-12 | $29.49M 10-Q · filed 2024-11-12 | $38.84M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $10.09M 10-Q · filed 2024-08-06 | $20.32M 10-Q · filed 2024-08-06 | $29.67M derived: sum of 3 quarters · filed 2025-02-27 | $33.54M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $10.23M 10-Q · filed 2024-05-08 | $19.58M derived: sum of 2 quarters · filed 2025-02-27 | $23.45M derived: sum of 3 quarters · filed 2025-02-27 | $24.63M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $9.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $13.22M derived: sum of 2 quarters · filed 2025-02-27 | $14.39M derived: sum of 3 quarters · filed 2025-02-27 | $14.58M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $3.87M 10-Q · filed 2023-11-07 | $5.05M derived: sum of 2 quarters · filed 2023-11-07 | $5.24M 10-Q · filed 2023-11-07 | $6.25M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $1.18M 10-Q · filed 2023-08-07 | $1.36M 10-Q · filed 2023-08-07 | $2.38M derived: sum of 3 quarters · filed 2024-02-27 | $3.10M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | $188.00K 10-Q · filed 2023-05-09 | $1.21M derived: sum of 2 quarters · filed 2024-02-27 | $1.92M derived: sum of 3 quarters · filed 2024-02-27 | $2.16M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.73M derived: sum of 2 quarters · filed 2024-02-27 | $1.98M derived: sum of 3 quarters · filed 2024-02-27 | $2.19M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $713.00K 10-Q · filed 2022-11-09 | $957.00K derived: sum of 2 quarters · filed 2022-11-09 | $1.17M 10-Q · filed 2022-11-09 | $2.54M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | $244.00K 10-Q · filed 2022-08-09 | $458.00K 10-Q · filed 2022-08-09 | $1.83M derived: sum of 3 quarters · filed 2023-03-01 | $2.70M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | $214.00K 10-Q · filed 2022-05-10 | $1.59M derived: sum of 2 quarters · filed 2023-03-01 | $2.45M derived: sum of 3 quarters · filed 2023-03-01 | $3.68M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $2.24M derived: sum of 2 quarters · filed 2023-03-01 | $3.46M derived: sum of 3 quarters · filed 2023-03-01 | $5.12M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $866.00K 10-Q · filed 2021-11-09 | $2.09M derived: sum of 2 quarters · filed 2021-11-09 | $3.75M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $1.23M 10-Q · filed 2021-08-09 | $2.88M 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | $1.66M 10-Q · filed 2021-05-10 | ||||
| 2019-12-31 | $8.23M 10-K · filed 2022-03-01 | ||||
| 2019-06-30 | $3.37M 6-K · filed 2020-09-11 | ||||
| 2018-12-31 | $3.26M 10-K · filed 2021-03-01 | $3.26M 20-F · filed 2019-03-29 | |||
| 2017-12-31 | $527.00K 20-F · filed 2020-04-29 | $527.35K 20-F · filed 2018-04-30 | |||
| 2016-12-31 | $403.27K 20-F · filed 2019-03-29 | ||||
| 2015-12-31 | $5.00K 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |